SPOTLIGHT: Hollis-Eden skyrockets on preclinical cancer data

At the 2007 ASCO Breast Cancer Symposium, Hollis-Eden reported impressive data for HE3235, a preclinical candidate for breast cancer. HE3235 significantly inhibited the incidence of new tumors and stopped the growth of existing tumors in a preclinical model of breast cancer. The company's stock shot up 30 percent on the news. Last week, Hollis-Eden was featured in FierceBiotech's weekly series on emerging drug developers. Release

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.